2025-09-28 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data you provided, presented in a structured and informative manner.

## Eli Lilly and Co. (LLY) Analysis

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (LLY):** 180.64%
*   **Cumulative Return (VOO):** 66.41%
*   **Absolute Outperformance:** 114.23% (LLY outperformed VOO by this much)
*   **Range of Outperformance (Max: 173.5, Min: -30.4, Current: 80.4)**
*   **Relative Outperformance:** 54.3 (This indicates that LLY's current outperformance is in the upper-middle range of its historical outperformance relative to VOO)

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO). The relative outperformance metric suggests that while LLY is doing well, it's not at its absolute peak compared to its historical performance relative to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2015-2017  | 7.0%   | 76.1%  | -3.0%  | -0.1  | 75.7   |
| 2016-2018  | 37.0%  | 68.8%  | 39.0%  | -0.0  | 103.7  |
| 2017-2019  | 39.0%  | 68.8%  | 35.0%  | -0.0  | 117.8  |
| 2018-2020  | 31.0%  | 79.7%  | 5.0%   | 0.0   | 151.4  |
| 2019-2021  | 56.0%  | 79.7%  | 28.0%  | 0.3   | 247.6  |
| 2020-2022  | 73.0%  | 79.7%  | 59.0%  | 0.3   | 328.0  |
| 2021-2023  | 121.0% | 78.8%  | 103.0% | 0.2   | 522.6  |
| 2022-2024  | 133.0% | 81.1%  | 120.0% | 0.2   | 692.1  |
| 2023-2025  | 70.0%  | 83.4%  | 35.0%  | 0.1   | 649.5  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR has been very strong in recent years, particularly in the 2021-2024 period.  The most recent period (2023-2025) shows a lower, though still healthy, growth rate.
*   **MDD (Maximum Drawdown):** The MDD is relatively high, indicating significant potential for price declines from peak to trough. This suggests higher volatility.
*   **Alpha:**  The Alpha values are predominantly positive and large, indicating significant excess returns compared to the market.
*   **Beta:** Beta values are low, suggesting that LLY's price movements are not highly correlated with the overall market.  In some periods, it's even negative, implying a slight inverse relationship.
*   **Cap(B) (Market Capitalization in Billions):**  The market capitalization has grown substantially over the analyzed periods, reflecting the company's growth.

### 2. Recent Stock Price Movements

*   **Current Price:** 724.54
*   **Previous Close:** 714.59
*   **Change:** 1.39% (Positive, showing an increase)
*   **5-Day Moving Average:** 735.86
*   **20-Day Moving Average:** 744.92
*   **60-Day Moving Average:** 742.96

**Analysis:**  The current price is below all three moving averages (5-day, 20-day, and 60-day). This *could* indicate a short-term downtrend or pullback. The positive change from the previous close offers some counterpoint. Further analysis would be needed to confirm.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 43.81 (Neutral - neither overbought nor oversold)
*   **PPO (Percentage Price Oscillator):** -0.51 (Slightly negative, indicating potential short-term weakness)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Recent (20-day) Relative Outperformance Change:** -4.2 (Negative - indicates short-term decline in outperformance)
*   **Expected Return:** 78.7% (Long-term expected outperformance vs. S&P 500)

**Analysis:**

*   The **high MRI** suggests the stock is considered a good investment opportunity based on risk assessment.
*   The **RSI** is neutral, not giving a strong buy or sell signal.
*   The **PPO** is slightly negative, suggesting potential short-term downward momentum.
*   The **Hybrid Signal** is strongly bullish, recommending full investment of available cash and suggesting a regular monthly investment.
*   The negative change in relative outperformance indicates a recent underperformance compared to the S&P 500.
*   The **high expected return** suggests that, over the long term (2+ years), the stock is projected to significantly outperform the S&P 500 if a regular investing strategy is used.
*   The significant positive price change since the last close (1.39%) suggests a potential rebound or positive reaction to recent news.

### 4. Recent News & Significant Events

*   **GLP-1 Competition:**  Articles discuss Pfizer's GLP-1 bet and increasing competition in the weight-loss drug market (Amgen entering the scene).  This is relevant to LLY because it is a major player in diabetes and weight management drugs.
*   **EU Approval of Kisunla:** The EU approval of Lilly's Kisunla for early Alzheimer's is a significant positive development.
*   **Trump's Tariff Threat:** News about Trump's potential pharma tariffs and the subsequent stock reactions (including LLY) indicates that the pharmaceutical sector is sensitive to political and trade policy news.

**Analysis:**  The news is mixed. The increased competition in the GLP-1 space could be a headwind. However, the EU approval of Kisunla is a major positive catalyst. The tariff news highlights political risks.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.78 (~Buy)
*   **Number of Opinions:** 26
*   **Target Price (avg/high/low):** 884.31 / 1190.00 / 650.00
*   **Recent Rating Changes:** No specific changes provided

**Analysis:** Analyst sentiment is generally positive, with a consensus "Buy" rating and a mean rating leaning towards "Buy." The average target price of 884.31 suggests significant upside potential from the current price.  The high target price (1190.00) reflects very bullish expectations from some analysts, while the low target price (650.00) suggests some caution.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출        |
|--------------|------|-------------|
| 2025-08-07   | 6.3  | 15.56 B$    |
| 2025-05-01   | 3.07 | 12.73 B$    |
| 2024-10-30   | 1.08 | 11.44 B$    |
| 2024-08-08   | 3.29 | 11.30 B$    |
| 2025-08-07   | 3.29 | 11.30 B$    |

**Analysis:**

*   The most recent EPS (6.3) and revenue (15.56 B$) show strong growth compared to previous periods.
*   The EPS and revenue figures have been generally trending upwards over the past several quarters.
*   The repeated date (2025-08-07) with different EPS and revenue figures is suspicious and needs clarification.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |
| 2024-06-30   | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-06-30   | $18.27B   | 30.98%  |
| 2025-03-31   | $15.76B   | 17.50%  |
| 2024-12-31   | $14.19B   | 31.07%  |
| 2024-09-30   | $14.24B   | 6.81%   |
| 2024-06-30   | $13.56B   | 21.88%  |

**Analysis:**

*   **Revenue and Profit Margin:**  Both revenue and profit margins have shown consistent growth, indicating strong business performance. The high profit margins suggest the company has pricing power and efficient operations.
*   **Equity and ROE:** Equity has been increasing, reflecting the company's retained earnings and asset growth. ROE (Return on Equity) is volatile but generally high, indicating efficient use of shareholder equity to generate profits.

### 7. Overall Summary

Eli Lilly and Co. (LLY) presents a compelling investment case based on the provided data, but with some considerations:

*   **Strengths:**
    *   Significant outperformance compared to the S&P 500.
    *   Strong CAGR, Alpha, and positive analyst ratings.
    *   Recent EU approval of Kisunla.
    *   Increasing revenue and profit margins.
    *   High expected return.
    *   Strong hybrid signal (recommendation).
    *   High MRI (High Investment Recommended)

*   **Weaknesses/Considerations:**
    *   High MDD indicating volatility.
    *   Increasing competition in the GLP-1 market.
    *   Political risks related to potential pharma tariffs.
    *   Short-term price is below moving averages, suggesting potential pullback.
    *   A duplicated/incorrect entry in the earning analysis.

**Conclusion:**  LLY appears to be a fundamentally strong company with positive growth prospects, especially in the long term. The recent price action suggests a possible short-term pullback, but the overall outlook remains bullish. Investors should monitor the competitive landscape in the GLP-1 market and any policy changes that could impact the pharmaceutical industry. The duplicated/incorrect earning data should be clarified.

**Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Consult with a qualified financial advisor before making any investment decisions.
